Nexentis Technologies (NXTS) Operating Margin (2019 - 2025)
Nexentis Technologies (NXTS) posted Operating Margin of 66300.0% for Q3 2025, down 6969.14% on a QoQ basis from 937.88% in Q1 2025, and down 5034444.0% year-over-year from N/an in Q3 2024.
Powered by 
Analysis
Nexentis Technologies (NXTS) Operating Margin (2019 - 2025) Analysis & Trends
Nexentis Technologies has reported Operating Margin for 7 years, with the latest figure at 66300.0% in Q3 2025.
- On a quarterly basis, Operating Margin fell 5034444.0% year-over-year to 66300.0% in Q3 2025; TTM through Sep 2025 was 2292.34%, a 74052.0% increase from a year earlier, with the FY2024 full-year figure at 1563.33%, up 131804.0% from the prior year.
- Operating Margin was 66300.0% for Q3 2025 at Nexentis Technologies, down from 937.88% in the prior quarter.
- The five-year high for Operating Margin was 155.32% in Q4 2024, with the low at 66300.0% in Q3 2025.
- Average Operating Margin over 5 years is 6570.29%, with a median of 2027.96% recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Operating Margin jumped 187264 bps in 2024, then slumped 5034444 bps in 2025.
- Over 5 years, Operating Margin stood at 830.25% in 2021, then climbed by 23 bps to 637.86% in 2022, then plunged by 218 bps to 2027.96% in 2023, then soared by 92 bps to 155.32% in 2024, then sank by 42586 bps to 66300.0% in 2025.
- The last three Operating Margin figures came in at 66300.0% (Q3 2025), 937.88% (Q1 2025), and 155.32% (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.59 Bn | 192.60 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.21 Bn | 177.03 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.41 Bn | 123.56 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.94 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.60 Bn | 55.41 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.61 Bn | 48.47 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.83 Bn | 30.54 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn | -25,380.93% |
| 10 | Nexentis Technologies | 1.35 Mn | -7.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -66,300.00% |
| Mar 31, 2025 | -937.88% |
| Dec 31, 2024 | -155.32% |
| Sep 30, 2024 | -15,955.56% |
| Jun 30, 2024 | -4,982.35% |
| Mar 31, 2024 | -2,043.18% |
| Dec 31, 2023 | -2,027.96% |
| Jun 30, 2023 | -2,295.45% |
| Mar 31, 2023 | -1,440.92% |
| Dec 31, 2022 | -637.86% |
| Sep 30, 2022 | -3,450.59% |
| Jun 30, 2022 | -4,108.53% |
| Mar 31, 2022 | -1,535.63% |
| Dec 31, 2021 | -830.25% |
| Sep 30, 2021 | -1,811.17% |
| Jun 30, 2021 | -2,981.71% |
| Mar 31, 2021 | -200.59% |
| Dec 31, 2020 | -89.90% |
| Mar 31, 2020 | -569.27% |
| Dec 31, 2019 | -1,198.43% |